<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Gastrointestinal (GI) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are the most common human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> encountered worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>The majority of GI <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are unresectable at the time of diagnosis, and in the subset of patients undergoing resection, few are cured </plain></SENT>
<SENT sid="2" pm="."><plain>There is only a modest improvement in survival with the addition of modalities such as chemotherapy and radiation therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Due to an increasing global <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> burden, it is imperative to integrate alternative strategies to improve outcomes </plain></SENT>
<SENT sid="4" pm="."><plain>It is well known that <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> possess diverse strategies to evade immune detection and destruction </plain></SENT>
<SENT sid="5" pm="."><plain>This has led to the incorporation of various immunotherapeutic strategies, which enable reprogramming of the immune system to allow effective recognition and killing of <z:e sem="disease" ids="C0017185" disease_type="Neoplastic Process" abbrv="">GI tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>METHODS: A review was conducted of the results of published clinical trials employing immunotherapy for esophageal, gastroesophageal, gastric, hepatocellular, pancreatic, and <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Monoclonal antibody therapy has come to the forefront in the past decade for the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Immunotherapeutic successes in solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> such as <z:hpo ids='HP_0002861'>melanoma</z:hpo> and <z:hpo ids='HP_0012125'>prostate cancer</z:hpo> have led to the active investigation of immunotherapy for GI <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, with some promising results </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: To date, monoclonal antibody therapy is the only immunotherapy approved by the US Food and Drug Administration for GI <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Initial trials validating new immunotherapeutic approaches, including vaccination-based and adoptive cell therapy strategies, for GI <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> have demonstrated safety and the induction of antitumor immune responses </plain></SENT>
<SENT sid="11" pm="."><plain>Therefore, immunotherapy is at the forefront of neoadjuvant as well as adjuvant therapies for the treatment and eradication of GI <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
</text></document>